Key Takeaways
- • Ampersand Capital Partners, a healthcare-focused private equity firm, closed its latest fund at $1.5 billion, reaching its target capitalization on May 28, 2026.
- • McDermott Will & Schulte served as legal advisor to Ampersand on the fund closing, underscoring the firm's reliance on top-tier legal counsel for institutional fund operations.
- • The fund closing demonstrates continued institutional investor appetite for healthcare-sector private equity, a traditionally defensive segment within alternative investments.
- • Ampersand's ability to raise $1.5 billion reflects confidence in the firm's track record and investment thesis within the healthcare vertical, a sector characterized by stable cash flows and demographic tailwinds.
Summary
Ampersand Capital Partners, a healthcare-focused private equity firm, announced the closing of its latest fund with $1.5 billion in committed capital on May 28, 2026. The fund reached its target size, signaling strong institutional investor demand for healthcare-sector exposure through private equity vehicles.
McDermott Will & Schulte, a major global law firm, served as legal advisor to Ampersand throughout the fund formation and closing process. The engagement reflects standard practice among institutional-grade private equity firms, which rely on specialized legal counsel to navigate regulatory requirements, investor documentation, and fund governance structures.
The successful fund close arrives amid a broader institutional appetite for healthcare private equity, driven by favorable sector fundamentals including aging demographics, resilient revenue streams, and consolidation opportunities within fragmented healthcare markets. For hedge fund managers and family offices seeking diversified exposure to alternative assets, healthcare PE funds have remained a core allocation within private equity portfolios.
McDermott Will & Schulte, a major global law firm, served as legal advisor to Ampersand throughout the fund formation and closing process. The engagement reflects standard practice among institutional-grade private equity firms, which rely on specialized legal counsel to navigate regulatory requirements, investor documentation, and fund governance structures.
The successful fund close arrives amid a broader institutional appetite for healthcare private equity, driven by favorable sector fundamentals including aging demographics, resilient revenue streams, and consolidation opportunities within fragmented healthcare markets. For hedge fund managers and family offices seeking diversified exposure to alternative assets, healthcare PE funds have remained a core allocation within private equity portfolios.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.